Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Kobeleva, Xenia ^a   Wegner, Florian ^a   Brunotte, Inez ^a   Dadak, Mete ^a   Dengler, Reinhard ^a   Stangel, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Multiple sclerosis; Natalizumab; Varicella zoster virus; Vasculitis

Indexed keywords

ACICLOVIR; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; NATALIZUMAB; PREDNISOLONE;

ADULT; ARTICLE; BRAIN VASCULITIS; CASE REPORT; CEREBROSPINAL FLUID; CONFUSION; DISEASE ASSOCIATION; DRUG MEGADOSE; FOLLOW UP; HEMIPARESIS; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; RELAPSE; RETINA VASCULITIS; VARICELLA ZOSTER VIRUS; VISUAL IMPAIRMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; FOLLOW-UP STUDIES; HERPES ZOSTER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 84893185059     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-19     Document Type: Article

References (15)

1. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66. 10.1038/356063a0, 1538783.
2. Chan PY, Aruffo A. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem 1993, 268:24655-24664.
3. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744.
4. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923. 10.1056/NEJMoa044396, 16510745.
5. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012, 366:1870-1880. 10.1056/NEJMoa1107829, 22591293.
6. Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis 2013, Epub ahead of print.
7. Kwiatkowski A, Gallois J, Bilbault N, Calais G, Mackowiak A, Hautecoeur P. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler 2012, 18:909-911. 10.1177/1352458511428082, 22048950.
8. Shenoy ES, Mylonakis E, Hurtado RM, Venna N. Natalizumab and HSV meningitis. J Neurovirol 2011, 17:288-290. 10.1007/s13365-011-0027-4, 3105891, 21487835.
9. Fragoso YD, Brooks JB, Gomes S, de Oliveira FT, da Gama PD. Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci Ther 2013, 19:280-281. 10.1111/cns.12067, 23419219.
10. Nagel MA, Traktinskiy I, Stenmark KR, Frid MG, Choe A, Gilden D. Varicella-zoster virus vasculopathy: immune characteristics of virus-infected arteries. Neurology 2013, 80:62-68. 10.1212/WNL.0b013e31827b1ab9, 3589199, 23243076.
11. Gilden DH, Mahalingam R, Cohrs RJ, Kleinschmidt-DeMasters BK, Forghani B. The protean manifestations of varicella-zoster virus vasculopathy. J Neurovirol 2002, 8(Suppl 2):75-79.
12. Amlie-Lefond C, Jubelt B. Neurologic manifestations of varicella zoster virus infections. Curr Neurol Neurosci Rep 2009, 9:430-434. 10.1007/s11910-009-0064-z, 19818229.
13. Nagel MA, Cohrs RJ, Mahalingam R, Wellish MC, Forghani B, Schiller A, et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008, 70:853-860. 10.1212/01.wnl.0000304747.38502.e8, 2938740, 18332343.
14. Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006, 59:743-747. 10.1002/ana.20858, 16634029.
15. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 2012, 71:604-617. 10.1097/NEN.0b013e31825caf2c, 22710964.